Skip to content
Catalyst

PapersPMID:41006034

Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma.

Anticancer research2025The record ↗

  1. Finding, insufficient evidencelowersEGFR

What moved

1 findingHow to read these marks →
  • Inhibits EGFR

    insufficient

    “EGCG also suppressed EGFR expression, especially in Hep3BLR.”
    Study
    in vitro · not in humans
    Dose studied
    10 μg/ml
    Population
    Hep3B human hepatocellular carcinoma cells and the lenvatinib-resistant Hep3BLR subline

Study record

Design
in vitro
Species
mixed
Population
Hep3B human hepatocellular carcinoma cells, lenvatinib-resistant (Hep3BLR) and sorafenib-resistant (Hep3BSR) sublines; nude mouse xenografts used for miR-575 mimic functional validation (not EGCG dosing)
Participants
not reported
Comparator
not stated in the paper
Duration
not reported
Endpoints measured
5